// App-Quantinova.ai

S4195 2015 AHA : Prognostic Value of Baseline BNP and NT-ProBNP and its Interaction with Spironolactone in Patients with Heart Failure and Preserved Ejection Fraction in the TOPCAT Trial

Researchers

Presenter

  • Scott D Solomon

Principal Investigators

  • Brian Claggett

  • Sanjiv J Shah

  • Eileen -Meara

  • Robin Boineau

  • Jerome L Fleg

  • Natl Heart

  • Marc A Pfeffer

  • Bertram Pitt

Medical Centers

  • Univ of Minnesota and VA Medical Ctr, Minneapolis and San Diego, Minneapolis, MN

  • and Blood Inst, Bethesda, MD

  • Brigham & Women's Hospital, Boston, MA

  • Univ of Michigan Sch of Med, Ann Arbor, MI

  • Northwestern Univ Feinberg Sch of Med, Chicago, Chicago, IL

  • Montreal Heart Institute, Montreal, Quebec, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Arrhythmia

  • Cardiac arrest

  • Congestive heart failure

  • Diabetes

  • Heart failure with preserved ejection fraction

Biomarkers

  • Body mass index

  • N-terminal pro b-type natriuretic peptide

Drug/Treatment

  • Spironolactone

  • Irbesartan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved